http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
최석환(Seock Hwan Choi),권태균(Tae Gyun Kwon) 대한비뇨기종양학회 2013 대한비뇨기종양학회지 Vol.11 No.1
The rapid and widespread use of prostate-specific antigen (PSA) screening into clinical field was based on the assumption that PSA may increase the chance of earlier detection and cure of prostate cancer with minimal harms. In US, the introduction of PSA testing nearly doubled the lifetime risk of receiving a diagnosis of prostate cancer. However, many studies reported that PSA screening also can increase overdiagnosis and subsequent overtreatment. To evaluate the value of PSA screening on prostate cancer mortality, numerous studies have been conducted with contradictory results. Moreover, most of them were not randomized, controlled study. Recently, early results of two large, randomized, controlled trials of screening have published. A European study showed a modest decrease in prostate-cancer mortality, whereas a United States study showed no decrease in prostate-cancer mortality. Considering these inconsistent results of trials, men considering prostate-cancer screening should be informed about the potential benefits and harms of screening and early treatment. In this article, we address the current status and value of PSA screening with the review of the literature on PSA screening for prostate cancer.
최석환(Seock Hwan Choi),권태균(Tae Gyun Kwon) 대한비뇨기종양학회 2012 대한비뇨기종양학회지 Vol.10 No.3
Urine cytology is one of the key screening and surveillance methods in the management of patients with urothelial tumors. Urine cytology usually shows high specificity and low sensitivity. Therefore, positive cytology is generally considered as a precursor of the urothelial malignancy even if there is no clinical confirmation. Clinically unconfirmed positive urine cytology refers to the condition that the result of urine cytology is repeatedly positive but the malignancy cannot be identified with the imaging study or cystoscopy. Based upon current reports, most patients with clinically unconfirmed positive urine cytology will eventually be identified with the recognizable tumors. In the present study cohort, the most common site of malignancy was the bladder. In this article, we address the systematic approach to evaluation and management of clinically unconfirmed positive urine cytology with the literature review.
전소영 ( So Young Chun ),오세행 ( Se Heang Oh ),유지 ( James J Yoo ),권태균 ( Tae Gyun Kwon ) 한국조직공학과 재생의학회 2015 조직공학과 재생의학 Vol.12 No.1s
Organ transplantation has often been successful for treatment of end-stage organ failure. However, the shortage of donor organ still remains problematic in clinical practices. As an alternative, the tissue-engineering approach for functional organ replacement has been extensively studied. More recently, decellularized organs have been emerged as a promising scaffold for reconstruction of the complicated organs (e.g., heart, liver, lung and kidney). The ideal decellularized organ scaffolds need to contain extracellular matrix (ECM), bioactive molecules, vascular systems and tissue microarchitecture. To fulfill these requirements, physical, chemical, and biological techniques have been adapted in the process of organ decellularization. In this review, the representative techniques for the organ decellularization and their characterization as well as considerations for implantation are discussed.
김지원(Jiwon Kim),이준녕(Jun Nyung Lee),하윤석(Yun-Sok Ha),권태균(Tae Gyun Kwon),이상규(Sangkyu Lee) 대한약학회 2020 약학회지 Vol.64 No.4
Prostate cancer is one of the most common male cancer. It tends to be known as “mild cancer” due to its high five-year survival rate. However, some patients develop castration-resistant prostate cancer (CRPC) during androgen deprivation therapy (ADT) treatment, with high metastasis and poor prognosis. In addition to conventional ADT treatments, specific treatments are implemented for CRPC. There are four second-generation anti-androgen drugs, taxane chemotherapy, and immunotherapy using vaccines and monoclonal antibodies. This review paper outlines the mechanism of prostate cancer leading to CRPC and reviews the standard treatment of CRPC. It also summarized the trends of anticancer drugs under clinical trials to obtain CRPC as an additional indication.
HLA 일배체 부적합 혈연관계 생체 신이식에서 공여자 연령이 이식신 및 환자 생존율에 미치는 영향
김준홍(Jun Hong Kim),김찬덕(Chan Duk Kim),김석재(Seog Jae Kim),백미영(Mi Young Baek),권태환(Tae Hwan Kwon),김용림(Yong Lim Kim),조동규(Dong Kyu Cho),김영욱(Young Wook Kim),권태균(Tae Gyun Kwon),장세국(Sae Kook Chang) 대한내과학회 1998 대한내과학회지 Vol.54 No.3
N/A Objectives: Renal transplantation has become the therapy of choice for patients suffering from end-stage renal disease. But because of progressive disparity between the number of patients in needs of a transplant and the number of ideal kidneys available for transplantation, increasing numbers of kidneys are recovered for transplantation from donors that are not considered ideal, especially from donors over the age of 55. In country such as Korea, the number of cadaveric transplants is limited due to cultural and religious prejudices of the population, poor legal definition and deficient organization of cadaveric donor work-up. Therefore the main source is living related donors(LRD), especially the parent. But in Korea, there is few reports about the influence of donor age on outcome in living related kidney transplantation. Thus we performed this study to estimate the influence of donor age in itself on the outcome of the one HLA-haplotype mismatched living related kidney transplantation. Methods: The effect of donor age on the outcome of One HLA-haplotype mismatched living related kidney transplantation was studied in 71 recipients who under- went kidney transplantation from January 1981 to March 1995. The outcomes of 25 recipients from the older age group(?55 years: Group A) and 46 recipients from the younger age group(<55 years: Group B) were retrospectively reviewed. Patient death with a functioning graft was considered graft loss. Results: Demographic characteristics between 2 groups were similar, The 1-year and 3-year patient survival rates in recipients(group A and B) were similar regardless of donor age(96.0% and 90.8% vs.97.4% and 90.3%, respectively). The 1-year and 3-year graft survival rates in recipients(group A and B) were not significantly different (91.4% and 63.9% vs 92.7% and 79.3%, respectively). The mean levels of serum creatinine at discharge were significantly higher in group A. Short-term and intermediate-term renal function, as assessed by serum creatinine, was inferior in the group A throughout the follow-up periods of 3 years. The causes of graft loss in the first 3 years after transplantation were irreversible rejection(71%) and the patient death with functioning graft(29%) in group A, while the causes of graft loss in group B were irreversible rejection(50%), patient death with a functioning graft(40%) and technical reason(10%). Conclusion: These results of our analysis suggest that similar outcome can be achieved after living related renal transplantation from older donor. Therefore the kidneys may be used from donors over 55 years old on condition that the donors undergo complete and exhaustive work-up.